Previous 10 | Next 10 |
Zhanna Hapanovich/iStock via Getty Images Ironwood Pharmaceuticals (IRWD) rose 3% after an 8-K filing about an amended severance and change in control agreement for CEO Tom McCourt sparked some takeover speculation. Ironwood appeared to gain after Dealreporter highlighted ...
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) traded at a new 52-week high today of $12.79. So far today approximately 101,000 shares have been exchanged, as compared to an average 30-day volume of 1.9 million shares. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is currently priced 27.6% ab...
– Results demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C – – LINZESS U.S. prescribing information updated in September 2020 to reflect Phase IIIb data – Ironwoo...
Inflation is here; and that means these groups ought to be on your radar. The best stocks within every sector now. Over 20 new stocks join our 'best stocks' list this week. For further details see: The Stocks To Focus On Today
Ironwood Pharmaceuticals (IRWD) announces the appointment of Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as the company's permanent chief executive officer.McCourt has also been appointed to serve on Ironwood’s bo...
– Thomas McCourt named permanent CEO and appointed to Ironwood Board of Directors – – Gina Consylman to step down as SVP, CFO effective July 2, 2021 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, toda...
Market leadership by sector and market cap. Sectors remain tilted toward mid-cycle ideas. However, stock-specific ideas are available in every basket. For further details see: The Top Stocks You Can Buy Now
The pharmaceutical sector received much investor attention amid the COVID-19 pandemic and their interest in this sector is expected to continue given the growing demand for pharmaceutical products and solutions. As such, we think it could be smart to bet on relatively undervalued pharma stock...
Ironwood Pharmaceuticals (IRWD) announced that the company with its partner AbbVie has reached an agreement with Teva Pharmaceuticals (TEVA) in granting a license related to a generic version of constipation med LINZESS (linaclotide).With the license for its abbreviated new drug applicat...
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with T...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...